[11C]PIB

DRUG5 trials

Sponsors

Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience, Johns Hopkins University, Peking Union Medical College Hospital, Yale University, Rigshospitalet, Denmark

Conditions

Alzeihmer diseaseAlzheimer Dementia (AD)Alzheimer's DiseaseAlzheimer's Disease (AD)Demyelinating DisordersDiabete Type 2MCIMS (Multiple Sclerosis)

Phase 1

PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers

CompletedNCT01826110

Johns Hopkins UniversityAlzheimer's Disease

Start: 2013-09-30End: 2018-07-31Updated: 2019-03-05

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

RecruitingNCT06999434

Yale UniversityAlzheimer's Disease (AD), Demyelinating Disorders, MCI +3

Start: 2025-05-05End: 2030-05-05Target: 105Updated: 2025-05-31

Phase 2

Impact of microglial activation on synaptic density in Alzheimer’s disease

Not yet recruitingCTIS2024-516566-11-00

Groupe Hospitalier Universitaire Paris Psychiatrie Et NeuroscienceAlzeihmer disease

Target: 90Updated: 2025-10-15

Unknown Phase

[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

Peking Union Medical College HospitalAlzheimer's Disease

Start: 2023-01-30End: 2025-12-31Target: 150Updated: 2023-11-21

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

RecruitingNCT07482072

Rigshospitalet, DenmarkAlzheimer Dementia (AD), Diabete Type 2

Start: 2026-03-01End: 2026-12-01Target: 60Updated: 2026-03-19

Related Papers

The diagnostic performance of [<sup>18</sup>F]Florbetazine in Alzheimer's disease: a head-to-head comparison to [<sup>11</sup>C]PiB and [<sup>18</sup>F]Florbetapir.

2025-04-04